
Fasudil (HA-1077) hydrochloride
CAS No. 105628-07-7
Fasudil (HA-1077) hydrochloride( HA-1077 | AT-877 )
Catalog No. M10257 CAS No. 105628-07-7
Fasudil hydrochloride(HA-1077; AT-877) is a potent inhibitor of ROCK-II, PKA, PKG, PKC, and MLCK.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
50MG | 32 | In Stock |
![]() ![]() |
100MG | 41 | In Stock |
![]() ![]() |
200MG | 61 | In Stock |
![]() ![]() |
500MG | 87 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameFasudil (HA-1077) hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionFasudil hydrochloride(HA-1077; AT-877) is a potent inhibitor of ROCK-II, PKA, PKG, PKC, and MLCK.
-
DescriptionFasudil hydrochloride(HA-1077; AT-877) is a potent inhibitor of ROCK-II, PKA, PKG, PKC, and MLCK with Ki of 0.33 μM, 1.6 μM, 1.6 μM, 3.3 μM and 36 μM, respectively.(In Vitro):Fasudil Hydrochloride (100 μM) inhibits cell spreading, the formation of stress fibers, and expression of α-SMA with concomitant suppression of cell growth in rat HSCs (hepatic stellate cells) and human HSC-derived TWNT-4 cells.Fasudil Hydrochloride (50-100 μM; 24 hours) inhibits the LPA (lysophoaphatidic acid)-induced phosphorylation of ERK1/2, JNK, and p38 detected by western blotting in rat HSCs and human HSC-derived TWNT-4 cells.Fasudil Hydrochloride (25-100 μM; 24 hours) suppresses transcription of collagen and TIMP, stimulates transcription of MMP-1 in human HSC-derived TWNT-4 cells. (In Vivo):Fasudil Hydrochloride (10 mg/kg; i.v.; 1 h before operation) exhibits protectable effects on cardiovascular disease and reduces the activation of JNK and attenuates mitochondrial-nuclear translocation of AIF under ischemic injury.Fasudil Hydrochloride (50 mg/kg/d; i.p.) inhibits acute and relapsing EAE (experimental autoimmune encephalomyelitis) induced by proteolipid protein PLP p139-151, reduces lymphocytes proliferation, results downregulation of interleukin (IL)-17 and a marked decrease of the IFN-γ/IL-4 ratio.Fasudil Hydrochloride (100 mg/kg/d; p.o.) significantly reduces incidence and pathological examination score of EAE (experimental autoimmune encephalomyelitis) in SJL/J mice, decreases inflammation, demyelination, axonal loss and APP positivein spinal cord in mice.
-
In VitroFasudil Hydrochloride (100 μM) inhibits cell spreading, the formation of stress fibers, and expression of α-SMA with concomitant suppression of cell growth in rat HSCs (hepatic stellate cells) and human HSC-derived TWNT-4 cells.Fasudil Hydrochloride (50-100 μM; 24 hours) inhibits the LPA (lysophoaphatidic acid)-induced phosphorylation of ERK1/2, JNK, and p38 detected by western blotting in rat HSCs and human HSC-derived TWNT-4 cells.Fasudil Hydrochloride (25-100 μM; 24 hours) suppresses transcription of collagen and TIMP, stimulates transcription of MMP-1 in human HSC-derived TWNT-4 cells. Western Blot Analysis Cell Line:Rat HSCs and human HSC-derived TWNT-4 cells Concentration:50 μM; 100 μM Incubation Time:24 hours Result:Suppressed the LPA-induced phosphorylation of ERK1/2, JNK and p38 MAPK by 60%, 70%,and 90%, respectively.RT-PCR Cell Line:Rat HSCs and human HSC-derived TWNT-4 cells Concentration:25 μM; 50 μM; 100 μM 24 hours Incubation Time:24 hours Result:Reduced the expression of type I collagen, a-SMA, and TIMP-1.
-
In VivoFasudil Hydrochloride (10 mg/kg; i.v.; 1 h before operation) exhibits protectable effects on cardiovascular disease and reduces the activation of JNK and attenuates mitochondrial-nuclear translocation of AIF under ischemic injury.?Fasudil Hydrochloride (50 mg/kg/d; i.p.) inhibits acute and relapsing EAE (experimental autoimmune encephalomyelitis) induced by proteolipid protein PLP p139-151, reduces lymphocytes proliferation, results downregulation of interleukin (IL)-17 and a marked decrease of the IFN-γ/IL-4 ratio.Fasudil Hydrochloride (100 mg/kg/d; p.o.) significantly reduces incidence and pathological examination score of EAE (experimental autoimmune encephalomyelitis) in SJL/J mice, decreases inflammation, demyelination, axonal loss and APP positivein spinal cord in mice. Animal Model:Myocardial ischemia and reperfusion in rat (250-300 g)Dosage:10 mg/kg Administration:Intravenous injection; 1 h before operation Result:Activated the Rho-kinase, JNK, and resulted AIF translocated to the nucleus.Inhibited Rho-kinase activity, and reduced myocardial infarct size and heart cell apoptosis.
-
SynonymsHA-1077 | AT-877
-
PathwayApoptosis
-
TargetPKA
-
RecptorPKA| PKG| PKC| ROCK2| MLCK
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number105628-07-7
-
Formula Weight327.83
-
Molecular FormulaC14H18ClN3O2S
-
Purity>98% (HPLC)
-
SolubilityWater: 65 mg/mL (198.27 mM); DMSO: 5 mg/mL (15.25 mM)
-
SMILESCl.Cl.O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ono-Saito N, et al. Pharmacol Ther, 1999, 82(2-3), 123-13
molnova catalog



related products
-
GUANOSINE 3':5'-CYCL...
GUANOSINE 3':5'-CYCLIC MONOPHOSPHATE also known as cGMP is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones including acetylcholine insulin and oxytocin.
-
H-89
H-89 is a selective and potent protein kinase A inhibitor (IC50: 48 nM), a candidate cardioprotectant, induces spatial learning impairment in rats, and can be used to study myocardial infarction.
-
AP-C2
AP-C2 is a potent small molecule guanosine 3',5'-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) inhibitor with a pIC50 of 5.2 for cGKII.